病毒学家李文辉：打开乙肝病毒之门

Core Viewpoint - The article highlights the significant contributions of Li Wenhui in the field of hepatitis B virus research and the establishment of the innovative pharmaceutical company Huahui Anjian, which is on the verge of launching a groundbreaking drug for hepatitis treatment. Group 1: Research Achievements - Li Wenhui discovered the hepatitis B virus receptor, a milestone that has transformed the understanding of hepatitis B infection mechanisms and drug development [8][25]. - The World Health Organization reported that viral hepatitis is the second leading cause of infectious disease deaths globally, with approximately 1.3 million deaths in 2022, 83% of which were due to hepatitis B [6][7]. - The receptor identified by Li's team, sodium-taurocholate co-transporting polypeptide (NTCP), was published in 2012 and is considered a pivotal discovery in hepatitis research [8][19]. Group 2: Company Development - Huahui Anjian, co-founded by Li Wenhui and his colleagues, has made significant progress in developing safer and more effective treatments for hepatitis B and D, with its leading drug, Libeweita, having its market application accepted by the National Medical Products Administration [18][19]. - The company emphasizes a culture of openness and high standards, ensuring that all team members are encouraged to engage in constructive criticism to foster innovation [18][19]. Group 3: Personal Insights and Philosophy - Li Wenhui believes that the essence of scientific research lies in the process of discovery rather than the accolades received, emphasizing the importance of exploration and problem-solving in science [11][12]. - He advocates for a research environment that allows for trial and error, which he credits as a key factor in the success of the Beijing Institute of Life Sciences [14][15].